Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Not stated	2026-01-29		NCT07374614

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Eighth Affiliated Hospital, Sun Yat-sen University	20
Longgang District People's Hospital of Shenzhen	9
Peking University Shenzhen Hospital	48
People Hospital of New District Longhua Shenzhen	1
Shenzhen People's Hospital	35
Sun Yat-Sen University Cancer Center	74
The First Affiliated Hospital of Guangzhou Medical University	95

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Shenzhen Hospital	Shenzhen	China	11